双特异性抗体在多发性骨髓瘤中的演进 The evolution of bispecific antibodies in multiple myeloma. PubMed 2026/02/01 发表Chin Clin OncolQ3 · IF 2.7(JCR 2025) 靶点:CD20靶点:CD38靶点:BCMA技术:双特异性抗体多发性骨髓瘤B细胞淋巴瘤淋巴瘤
靶向 CD79b 的三种新型 CAR 用于非霍奇金淋巴瘤治疗的临床前开发及靶抗原丢失特征分析 Preclinical development of three novel CARs targeting CD79b for the treatment of non-Hodgkin's lymphoma and characterization of the loss of the target PubMed 2024/12/18 发表J Immunother CancerQ1 · IF 11.7(JCR 2025) 基于特异性、疗效和靶抗原丢失,CARLY3 代表了一种针对非霍奇金淋巴瘤的潜在新型 CAR 治疗。 人群:成人靶点:CD19靶点:CD20靶点:CD22技术:CAR-T淋巴瘤
ARI0003:共转导 CD19/BCMA 双靶向 CAR-T 细胞治疗非霍奇金淋巴瘤 ARI0003: Co-transduced CD19/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma. PubMed 2024/11/19 发表Mol TherQ1 · IF 11.4(JCR 2025) 靶点:CD19靶点:CD20靶点:CD22技术:CAR-T非霍奇金淋巴瘤地区:欧洲
2023 年美国 FDA 批准的治疗性抗体的结构与功能 Structure and function of therapeutic antibodies approved by the US FDA in 2023. PubMed 2024/03/19 发表Antib TherQ2 · IF 4.8(JCR 2025) 人群:儿童靶点:CD20靶点:BCMA靶点:GPRC5D技术:双特异性抗体弥漫大B细胞淋巴瘤多发性骨髓瘤淋巴瘤